Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyclophosphamide
Drug ID BADD_D00549
Description Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Indications and Usage Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
Marketing Status Prescription; Discontinued
ATC Code L01AA01
DrugBank ID DB00531
KEGG ID D00287
MeSH ID D003520
PubChem ID 2907
TTD Drug ID D0CT9C
NDC Product Code 16714-859; 55150-270; 16714-857; 68001-443; 10019-943; 70121-1239; 70121-1240; 10019-945; 50742-521; 16714-858; 42973-318; 68001-442; 70121-1238; 65124-0003; 68001-444; 69097-517; 58623-0024; 10019-984; 55150-271; 10019-935; 57884-0022; 10019-942; 72603-104; 69097-516; 10019-955; 72603-411; 71052-223; 0781-3244; 63759-7008; 62559-930; 10019-938; 10019-944; 51927-0221; 15308-0921; 14593-910; 38779-0506; 10019-957; 51927-4871; 10019-936; 54879-021; 54879-022; 50742-520; 72603-326; 0054-0383; 0781-3255; 76339-164; 62559-931; 57821-004; 10019-982; 10019-939; 70860-218; 0054-0382; 50742-519; 68554-0062; 10019-937; 0781-3233; 10019-956
Synonyms Cyclophosphamide | Sendoxan | B-518 | B 518 | B518 | Cyclophosphamide Anhydrous | Cyclophosphamide, (R)-Isomer | Cyclophosphamide, (S)-Isomer | Cytophosphane | Cyclophosphamide Monohydrate | Cytophosphan | Cytoxan | Endoxan | Neosar | NSC-26271 | NSC 26271 | NSC26271 | Procytox | (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate | Cyclophosphane
Chemical Information
Molecular Formula C7H15Cl2N2O2P
CAS Registry Number 50-18-0
SMILES C1CNP(=O)(OC1)N(CCCl)CCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
CardiotoxicityTroponin I, fast skeletal muscleP48788Not Available11535996; 11109196; 10076722
ChromaturiaUroporphyrinogen decarboxylaseP06132Not Available3410226; 7165364; 7428280; 6714509
Cystitis noninfectiveCytochrome P450 2D6P10635T5739210569621; 15099680; 7490886
Gastrointestinal signs and symptomsLadinin-1P57016Not Available3501798; 3486225; 2276698
Gastrointestinal signs and symptomsB-cell antigen receptor complex-associated protein alpha chainP11911Not Available3501798; 3486225; 2276698
Gastrointestinal signs and symptomsInterleukin-4P07750Not Available3501798; 3486225; 2276698
Haemolytic anaemiaGlucose-6-phosphate 1-dehydrogenaseP11413T634844029094; 3603576; 6435286; 3007082; 3980359; 11703568; 9202959; 1275087; 3053584; 643379; 9316488
HypertrichosisUroporphyrinogen decarboxylaseP06132Not Available3410226; 7165364; 7428280; 6714509
Porphyrin metabolism disorderUroporphyrinogen decarboxylaseP06132Not Available3410226; 7165364; 7428280; 6714509
Pulmonary toxicitySuperoxide dismutase [Cu-Zn]P00441T229774029094; 3603576; 6435286; 3007082; 3980359; 11703568; 9202959; 1275087; 3053584; 643379; 9316488
Pulmonary toxicityGlucose-6-phosphate 1-dehydrogenaseP11413T634844029094; 3603576; 6435286; 3007082; 3980359; 11703568; 9202959; 1275087; 3053584; 643379; 9316488
Pulmonary toxicityGlutathione reductase, mitochondrialP00390T308034029094; 3603576; 6435286; 3007082; 3980359; 11703568; 9202959; 1275087; 3053584; 643379; 9316488
Pulmonary toxicityGlutathione peroxidase 1P07203T706544029094; 3603576; 6435286; 3007082; 3980359; 11703568; 9202959; 1275087; 3053584; 643379; 9316488
Skin hyperpigmentationUroporphyrinogen decarboxylaseP06132Not Available3410226; 7165364; 7428280; 6714509
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pigmentation disorder23.05.03.001--Not Available
Venoocclusive disease24.03.02.016--Not Available
Renal impairment20.01.03.010--Not Available
Muscle contracture15.03.01.010--Not Available
Carditis02.01.05.001--Not Available
Cystitis noninfective20.03.02.001--
Gene mutation03.12.02.002--Not Available
Bone marrow failure01.03.03.005--
Ureteric haemorrhage20.06.01.003; 24.07.07.001--Not Available
Organising pneumonia22.01.02.008--Not Available
Renal cell carcinoma20.01.04.003; 16.08.02.002--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.016--
Wound healing normal13.15.01.034--Not Available
Microsomia08.01.03.056--Not Available
Posterior reversible encephalopathy syndrome17.13.02.007--
Granulomatosis with polyangiitis24.05.02.013; 22.01.01.015; 20.05.01.013; 10.02.02.018--Not Available
Noninfective sialoadenitis07.06.04.003--Not Available
Drug cross-reactivity08.06.01.026; 10.01.01.020--Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Myeloproliferative neoplasm16.21.03.006; 01.13.03.006--Not Available
The 10th Page    First    Pre   10    Total 10 Pages